Grifols (GRFS) Equity Income (2010 - 2020)
Grifols' (GRFS) quarterly Equity Income came in at -$6.0 million in Q1 2020, up 11.9% YoY from -$5.4 million in Q2 2019, and up 70.81% on a QoQ basis from -$20.6 million in Q4 2019.
Grifols (GRFS) Equity Income (2010 - 2020) Analysis & Trends
Grifols (GRFS) has 6 years of Equity Income data on file, last reported at -$6.0 million in Q1 2020.
- Quarterly Equity Income rose 11.9% year-over-year to -$6.0 million in Q1 2020, while the trailing twelve-month figure through Mar 2020 was -$42.5 million (down 39.21% YoY) and the FY2019 annual result came in at -$20.6 million, down 127.41% from the prior year.
- Equity Income advanced to -$6.0 million in Q1 2020, from -$20.6 million in the prior quarter.
- In the past five years, Equity Income ranged from a high of -$2.5 million in Q1 2018 to a low of -$20.6 million in Q4 2019.
- A 4-year average of -$8.7 million and a median of -$6.8 million in 2019 frame the typical range for Equity Income.
- Annual changes were most pronounced in 2018 — Equity Income advanced 27.69% — and 2019, when it plunged 169.62%.
- Tracing GRFS's Equity Income over 4 years: stood at -$12.1 million in 2017, then climbed by 25.21% to -$9.1 million in 2018, then tumbled by 127.41% to -$20.6 million in 2019, then surged by 70.81% to -$6.0 million in 2020.
- The last three Equity Income figures came in at -$6.0 million (Q1 2020), -$20.6 million (Q4 2019), and -$6.8 million (Q1 2019), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | - |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | - |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | -2.00 Mn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | -10.00 Mn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | - |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | - |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | - |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | -4.03 Mn |
| 10 | Grifols | 5.45 Bn | 4.45 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | -6.02 Mn |
| Dec 31, 2019 | -20.62 Mn |
| Mar 31, 2019 | -6.83 Mn |
| Dec 31, 2018 | -9.07 Mn |
| Mar 31, 2018 | -2.53 Mn |
| Dec 31, 2017 | -12.12 Mn |
| Mar 31, 2017 | -3.50 Mn |
| Dec 31, 2011 | 2.70 Mn |
| Sep 30, 2011 | -190,975.93 |
| Dec 31, 2010 | 1.91 Mn |
| Sep 30, 2010 | -76,185.09 |